The Triage Gap in an Otherwise Functional RBM Setup
The problem isn't the signal detection infrastructure — Medidata Acorn AI is generating actionable data. The problem is the layer between signal output and CRA scheduling. With 40 to 60 signals per week and no structured triage logic, the default is human pattern-matching: CRAs visit sites they know, sites with high enrollment, sites that are easy to schedule. Low-volume sites with real data quality problems stay invisible until a protocol deviation surfaces or a site audit catches something. In a Phase II/III oncology trial, those undetected findings can affect data integrity, site performance evaluations, and ultimately the trial's data package. Vault CTMS has the visit history; Acorn AI has the signal data — but nothing is connecting them to produce a prioritized schedule.
Signal Scoring That Connects Acorn AI Output to CRA Bandwidth
An AI Labor Company agent extracts signal triage logic from Medidata Acorn AI's historical findings and Vault CTMS visit records — specifically the patterns that predicted actual data quality findings versus signals that resolved without on-site intervention. It deploys an agent that scores each week's RBM signal output by predictive value, weighing signal type, site history, enrollment volume, and prior finding patterns. The output is a ranked site visit schedule, generated weekly and routed to the clinical quality head for approval before CRA assignments are made. Rather than replacing CRA judgment, the agent structures the decision: your team reviews a prioritized list rather than an unordered signal queue. Teams operating this way typically redirect meaningful CRA bandwidth to genuinely high-risk sites, with estimated reductions in undetected data quality findings around 40%.
The Business Case: Protecting the Data Package
In oncology CRO work, the commercial risk of data quality failures isn't just remediation cost — it's sponsor confidence, contract renewals, and the CRO's regulatory track record. A site with undetected data quality issues that surfaces during FDA review creates work that is far more expensive than a well-timed on-site visit. The annual cost of this monitoring inefficiency runs $1M to $4M, reflecting CRA time misdirected to low-risk sites while high-risk ones accumulate findings. An agent that re-routes that bandwidth through predictive scoring recovers monitoring quality without adding CRA headcount. For a 300-to-1500-FTE commercial CRO running multiple Phase II/III oncology programs simultaneously, that quality improvement compounds across trials and strengthens the data package that sponsors ultimately present to regulators.
How does the agent learn which signal types are actually predictive for our specific trial designs?
The agent extracts predictive patterns from your Acorn AI historical findings and Vault CTMS visit records — which signal types led to confirmed on-site findings versus false positives across your prior trials. It applies those patterns to score new signals rather than using generic weights, so the triage logic reflects your actual trial population and site characteristics.
Does the agent change the CRA visit schedule directly, or does it require clinical quality head approval?
Every ranked visit schedule is routed to the Head of Clinical Quality for approval before CRA assignments are made. The agent produces the prioritized recommendation; your clinical quality leadership retains scheduling authority and can override any site ranking based on context the agent doesn't have.